Most Read Articles
05 Aug 2017
Discontinuation of antihypertensive drugs appears to have a detrimental effect, with a recent study reporting that the risk of acute myocardial infarction (AMI) substantially increases after more than 90 days of discontinuation.
Roshini Claire Anthony, 15 hours ago

Once-weekly doses of the glucagon-like peptide-1 receptor agonist exenatide plus insulin glargine improved glucose control and weight loss in patients whose type 2 diabetes (T2D) was uncontrolled on basal insulin and metformin, according to findings from the DURATION-7* trial.

03 Aug 2017
Cetuximab and docetaxel is safe and effective during postoperative radiotherapy for high-risk head and neck cancer patients who cannot receive cisplatin, a new study has found.
08 Sep 2017
Prediagnostic statin exposure appears to be associated with a significant reduction in breast cancer-specific mortality, with the survival benefit being more pronounced in women with oestrogen receptor (ER)-positive tumours, according to a study.

Glucagon-blocking drug reduces need for insulin, improves blood glucose levels in T1D patients

Audrey Abella
22 Jun 2017

A single dose of the human glucagon receptor (GCGR) antibody, REMD-477, reduces the amount of insulin necessary and significantly improves glycaemic control in individuals with type 1 diabetes (T1D), according to a study presented at the ADA 2017 in San Diego, California, US.

“[P]eople with [T1D] produce too much glucagon … Our study strongly supports the long-held theory that blocking glucagon may have a significant clinical impact on care for people with [T1D] by improving glucose levels and lowering insulin doses,” said Dr Jeremy Pettus from the University of California, San Diego, California, US.

In this double-blind study on 21 adults with T1D, patients were randomized to receive a single subcutaneous injection of REMD-477 (70 mg, n=10) or placebo injection (n=11) on day 2 of a 5-day, inpatient observation period. [ADA 2017, abstract 378-OR]

Glucose levels were measured using Continuous Glucose Monitoring prior to and 8 weeks after admission. Participants were given standardized meals and constant intravenous insulin infusion to help maintain glucose levels.

On day 4, REMD-477 administration resulted in a 26 percent (12 units) reduction in insulin levels vs placebo (p=0.02). “Exposure to this [GCGR] significantly reduced insulin requirements during inpatient stay,” said Pettus.

Furthermore, during the three weekly periods after inpatient evaluation, there was a significant improvement in blood sugar levels as the average daily glucose concentration in REMD-477-treated patients was 20–31 mg/dL lower than the placebo group (p<0.05), with less insulin use.

Pettus underlined that if the difference in blood sugar levels persisted, it would be equivalent to a HbA1C drop of about 1 percent, which translates to a substantial change in glucose profiles.

Outpatient glycaemic control evaluation during the second treatment week (days 6–12) showed a statistically significant increase in time-in-range in the REMD-477 vs placebo group (71 vs 56 percent).

Overall, these findings demonstrate that a single REMD-477 injection effectively reduced total daily insulin requirements while improving glucose control, with no episodes of severe hypoglycaemia, said the researchers.

“We expected that [REMD-477] would have an effect, yet the degree to which the drug reduced the need for insulin and improved patients’ blood sugar levels without increasing hypoglycaemia events was a surprise,” said Pettus.

As the study measured the glucagon-blocking effect after one injection only, Pettus indicated that a follow-up study has been initiated to evaluate long-term treatment using different dose strengths in order to determine the impact of REMD-477 on blood glucose levels, insulin use, and weight in an outpatient setting.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
05 Aug 2017
Discontinuation of antihypertensive drugs appears to have a detrimental effect, with a recent study reporting that the risk of acute myocardial infarction (AMI) substantially increases after more than 90 days of discontinuation.
Roshini Claire Anthony, 15 hours ago

Once-weekly doses of the glucagon-like peptide-1 receptor agonist exenatide plus insulin glargine improved glucose control and weight loss in patients whose type 2 diabetes (T2D) was uncontrolled on basal insulin and metformin, according to findings from the DURATION-7* trial.

03 Aug 2017
Cetuximab and docetaxel is safe and effective during postoperative radiotherapy for high-risk head and neck cancer patients who cannot receive cisplatin, a new study has found.
08 Sep 2017
Prediagnostic statin exposure appears to be associated with a significant reduction in breast cancer-specific mortality, with the survival benefit being more pronounced in women with oestrogen receptor (ER)-positive tumours, according to a study.